Predictors ofdually diagnosed patients' psychiatric symptom exacerbation during acute substance use disorder treatment

Journal of Dual Diagnosis

Volumn 4, Issue 1, 2008, Pages 55-74

  Timko, Christine ^a   Ilgen, Mark ^a   Moos, Rudolf H ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dual diagnosis; Psychiatric; Substance abuse; Symptom exacerbation; Treatment planning

Indexed keywords

ACUTE DISEASE; ADULT; ALCOHOLISM; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DEPENDENCE; DYSTHYMIA; FOLLOW UP; HEALTH PROGRAM; HOSPITAL DISCHARGE; HUMAN; MAJOR DEPRESSION; MENTAL HEALTH SERVICE; OUTPATIENT CARE; PATIENT COUNSELING; POSTTRAUMATIC STRESS DISORDER; PREDICTOR VARIABLE; RISK FACTOR; SCHIZOPHRENIA; SUBSTANCE ABUSE; VOCATIONAL GUIDANCE;

EID: 67650568874     PISSN: 15504263     EISSN: 15504271     Source Type: Journal    
DOI: 10.1300/J374v04n01_04     Document Type: Article

References (71)

1. McFarland BH, Gabriel RM. Service availability for persons with co-occurring conditions. Psychiatr Serv 2004; 55: 978.
2. Mojtabai R. Which substance abuse treatment facilities offer dual diagnosis programs? Am J Drug Alcohol Abuse 2004; 30: 525-36.
3. Timko C, Dixon K, Moos RH. Treatment for dual diagnosis patients in the psychiatric and substance abuse systems. Ment Health Serv Res 2005; 7: 229-242.
4. Ilgen M, Moos R. Deterioration following alcohol-use disorder treatment in project MATCH. J Stud Alcohol 2005; 66: 517-525.
5. Moos RH. Iatrogenic effects of psychosocial interventions for substance use disorders. Addiction 2005; 100: 595-604.
6. Shaw G K, Waller S, Latham C J, Dunn G, Thomson AD. Alcoholism: A long-term follow-up study of participants in an alcohol treatment programme. Alcohol Alcohol 1997; 32: 527-535.
7. Drake RE, Mercer-McFadden C, Mueser KT, McHugo GJ, Bond GR. Review of integrated mental health and substance abuse treatment for patients with dual disorders. Schizophr Bull 1998; 24: 589-608.
8. Drake, RE, Essock SM, Shanner A, Carey KB, Minkoff K, Kola L, Lynde D, Osher FC, Clark RE, Rickards L. Implementing dual diagnosis services for clients with severe mental illnesses. Psychiatr Serv 2001; 52: 469-476.
9. Graham HL. Implementing integrated treatment for co-existing substance use and severe mental health problems in assertive outreach teams. Drug Alcohol Rev 2004; 23: 463-70.
10. Moos RH, Nichol AC, Moos B S. Risk factors for symptom exacerbation among treated patients with substance use disorders. Addiction 2002; 97: 75-83.
11. Booth BM, Yates WR, Petty F, Brown K. Patient factors predicting early alcohol-related readmissions for alcoholics. J Stud Alcohol 1991; 52: 37-43.
12. McLellan AT, Alterman, AI, Metzger DS, Grissom GR, Woody GE, Luborsky L, O'Brien CP. Similarity of outcome predictors across opiate, cocaine, and alcohol treatments. J Consult Clin Psychol 1994; 62: 1141-1158.
13. Phibbs CS, Swindle RW, Recine B. Does case mix matter for substance abuse treatment? Health Servi Res 1997 31: 755-771.
14. Alterman AI, Cacciola JS The antisocial personality disorder diagnosis in substance abusers. J Nerv Ment Dis 1991; 179: 401-409.
15. Hendryx MS, Dyck DG, Srebnik D. Risk-adjustment outcome models for public health outpatient programs. Health Serv Res 1999; 34: 171-195.
16. Ouimette PC, Moos RH, Finney JW. Influence of outpatient treatment and 12-step group involvement on one-year substance abuse treatment outcome. J Stud Alcohol 1998; 59: 513-522.
17. Ilgen M, Moos R. Exacerbation of psychiatric symptoms during substance use disorder treatment. Psychiatr Serv in press.
18. Mohr DC. Negative outcome in psychotherapy. Clin Psychol 1995; 2: 1-27.
19. Mohr DC, Beutler LE, Engle D, Shoham-Salomon V, Bergan J, Kaszniak AW, Yost E. Identification of patients at risk for nonresponse and negative outcome in psychotherapy. J Consult Clin Psychol 1990; 58:622-628.
20. Shaw GK, Waller S, McDougall S, MacGarvie J, Dunn G. Alcoholism: A follow-up study of participants in an alcohol treatment programme. Br J Psychiatry 1990; 157: 190-196.
21. Burnam MA, Morton SC, McGlynn EA, Peterson LP, Stecher BM, Hayes C, Vaccaro JV. An experimental evaluation of residential and nonresidential treatment for dually diagnosed homeless adults. J Addict Dis 1995; 14: 111-34.
22. Carey KB, Carey MP, Maisto SA, Purnine DM. The feasibility of enhancing psychiatric outpatients' readiness to change their substance use. Psychiatr Serv 2002; 53: 602-8.
23. Drake RE, Mueser KT. Psychosocial approaches to dual diagnosis. Schizophr Bull 2000; 26: 105-118.
24. Greenfield SF, Weiss RD, Tohen M. Substance abuse and the chronically mentally ill: A description of dual diagnosis treatment services in a psychiatric hospital. Community Ment Health J 1995; 31: 265-277.
25. Hellerstein, DJ, Rosenthal RN, Miner CR. Integrating services for schizophrenia and substance use. Psychiatr Q 2001; 72: 291-306.
26. Minkoff K, Members of the CMHS Managed Care Initiative Panel on Co-Occurring Disorders. Co-occurring psychiatric and substance disorders in managed care systems: Standards of care, practice guidelines, workforce competencies, and training curricula. Philadelphia, PA: Center for Mental Health Policy and Services Research; 1998.
27. Mowbray CT, Solomon M, Ribisl KM, Ebejer MA, Deiz N, Brown W, Bandla H, Luke DA, Davidson WS, Hersman S. Treatment for mental illness and substance abuse in a public psychiatric hospital. J Subst Abuse Treat 1995; 12: 129-39.
28. Sacks S, Ries R. Substance abuse treatment for persons with co-occurring disorders. Washington, D.C.: CSAT TIPs; 2002.
29. Mueser KT, Noordsy DL, Drake RE, Fox L. Integrated treatment for dual disorders. New York, NY: Guilford; 2003.
30. Alam DA, Janicak PG. The role of psychopharmacotherapy in improving the long-term outcome of schizophrenia. Essent Psychopharmaco 2005; 6: 127-40.
31. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M,Scott J, Wittchen HU. Evidence-based guidelines for the pharmacological treatment of anxiety disorders. J Psychopharmacol 2005; 19: 567-96.
32. Perlis RH. The role of pharmacologic treatment guidelines for bipolar disorder. J Clin Psychiatry 2005; 66 Suppl: 37-47.
33. Buonopane A, Petrakis H Pharmacotherapy of alcohol use disorders. Subst Use Misuse 2005; 40: 2001-20.
34. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O'Brien CP. Injectable, sustained-release naltrexone for the treatment of opioid dependence. Arch Gen Psychiatry 2006; 63: 210-8.
35. Carey KB, Purnine DM, Maisto SA, Carey MP, Simons JS. Treating substance abuse in the context of severe and persistent mental illness. J Subst Abuse Treat 2000; 19: 189-198.
36. Davis KE, O'Neill SJ. A focus group analysis of relapse prevention strategies for persons with substance use and mental disorders. Psychiatr Serv 2005; 45:1288-91.
37. Fallot RD, Heckman JP. Religious/spiritual coping among women trauma survivors with mental health and substance use disorders. J Behav Health Serv Res 2005; 32: 215-226.
38. McDowell D, Galanter M, Goldfarb L, Lifshutz H. Spirituality and the treatment of the dually diagnosed. J Addict Dis 1996; 15: 55-68.
39. Goldfarb LM, Galanter M, McDowell D, Lifshutz H, Dermatis H. Medical student and patient attitudes toward religion and spirituality in the recovery process. Am J Drug Alcohol Abuse 1996; 22: 549-61.
40. Hammond A. Substance use and serious mental illness: Spiritual care. Nurs Stand 2003; 18: 33-8.
41. Greenfield SF, Weiss RD, Tohen M. Substance abuse and the chronically mentally ill: A description of dual diagnosis treatment services in a psychiatric hospital. Community Ment Health J 1995; 31: 265-277.
42. Mueser KT, Fox L. A family intervention program for dual disorders. Community Ment Health J 2002; 38: 253-270.
43. Weider BL, Lutz WJ, Boyle P. Adapting integrated dual disorders treatment for inpatient settings. Journal of Dual Diagnosis 2005; 2: 101-107.
44. McLellan AT, Alterman A I, Cacciola J, Metzger D, O'Brien C P. A new measure of substance abuse treatment: Initial studies of the treatment services review. J Nerv Ment Dis 1992; 180: 101-110.
45. Breslin FC, Borsoi D, Cunningham JA, Koski-Jannes A. Help-seeking timeline followback for problem drinkers: Preliminary comparison with agency records of treatment contacts. J Stud Alcohol 2001; 62: 262-7.
46. Killeen TK, Brady KT, Gold PB, Tyson C,Simpson KN. Comparison of self-report versus agency records of service utilization in a community sample of individuals with alcohol use disorders. Drug Alcohol Depend 2004; 73: 141-7.
47. Morgenstern J, Labouvie E, McCrady BS, Kahler CW, Frey RM (1997). Affiliation with Alcoholics Anonymous after treatment: A study of its therapeutic effects and mechanisms of action. J Consult Clin Psychol 1997; 65: 768-777.
48. Tonigan JS, Toscova R, Miller WR. Meta-analysis of the literature on Alcoholics Anonymous: Sample and study characteristics moderate findings. J Stud Alcohol 1996; 57: 65-72.
49. Castel S, Rush B, Urbanoski K, Toneatto T. Overlap of clusters of psychiatric symptoms among clients of a comprehensive addiction treatment service. Psychol Addict Behav 2006; 20: 28-35.
50. Charney DA, Palacios-Boix J, Negrete JC, Dobkin PL, Gill KJ. Association between concurrent depression and anxiety and six-month outcome of addiction treatment. Psychiatr Serv 56:927-33.
51. Dermatis H, Galanter M, Egelko S, Westreich L. Schizophrenic patients and cocaine use. Subst Abuse 1998; 19:169-177.
52. Todd J, Green G, Harrison M, Ikuesan BA, Self C, Pevalin DJ, Baldacchino A. Social exclusion in clients with comorbid mental health and substance use problems. Soc Psychiatry Psychiatr Epidemiol 2004; 39: 581-7.
53. Hudson TJ, Owen RR, Thrush CR, Han X, Pyne JM, Thapa P, Sullivan G. A pilot study of barriers to medication adherence in schizophrenia. J Clin Psychiatry 2004; 65: 211-216.
54. Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J, Weiden PJ. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000; 51: 216-22.
55. Tucker JS, D'Amico EJ, Wenzel SL, Golinelli D, Elliott MN, Williamson S. A prospective study of risk and protective factors for substance use among impoverished women living in temporary shelter settings in Los Angeles County. Drug Alcohol Depend 2005; 80: 35-43.
56. Jackson JL, Houston JS, Hanling SR, Terhaar KA, Kun JS. Clinical predictors of mental disorders among medical outpatients. Arch Intern Med 2001; 161: 875-9.
57. Mueser, KT, Drake RE, Sigmon SC, Brunette MF. Psychosocial interventions for adults with severe mental illnesses and co-occurring substance use disorders: A review of specific interventions. Journal of Dual Diagnosis 2005; 1: 57-82.
58. Ayuso-Gutierrez JL, del Rio Vega JM. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res 1997; 19: 199-206.
59. Ouimette PC, Moos RH, Finney JW. PTSD treatment and 5-year remission among patients with substance use and posttraumatic stress disorders. J Consult Clin Psychol 2003; 71: 410-4.
60. Laudet AB, Magura S, Vogel HS, Knight E. Support, mutual aid, and recovery from dual diagnosis. Community Ment Health J 2000; 36: 457-76.
61. Calsyn DA, Saxon AJ, Blaes P, Lee-Meyer S. Staffing patterns of American methadone maintenance programs. J Subst Abuse Treat 1990; 7: 255-259.
62. Rodgers JH, Barnett PG. Two separate tracks? A national multivariate analysis of differences between public and private substance abuse treatment programs. Am J Drug Alcohol Abuse, 2000; 26: 429-42.
63. Rosenheck RA, Desai R, Steinwachs D, Lehman A. Benchmarking treatment of schizophrenia: A comparison of service delivery by the national government and by state and local providers. J Nerv Ment Dis 2000; 18: 209-16.
64. Agha Z, Lofgren RP, VanRuiswyk JV, Layde PM. Are patients at Veterans Affairs medical centers sicker? Arch Intern Med 2000; 160: 3252-7.
65. Moggi F, Ouimette PC, Finney JW, Moos RH. Effectiveness of treatment for substance abuse and dependence for dual diagnosis patients: A model of treatment factors associated with one-year outcomes. J Stud Alcohol 1999; 60: 856-866.
66. Chi FW, Satre DD, Weisner C. Chemical dependence patients with co-occurring psychiatric diagnoses. Alcohol Clin Exp Res 2006; 30: 851-859.
67. Mayes J, Handley S. Evolving a model for integrated treatment in a residential setting for people with psychiatric and substance use disorders. Psychiatr Rehabil J 2005; 29: 59-62.
68. Mowbray CT, Solomon M, Ribisl KM, Ebejer MA, Diez N, Brown W, Bandla H, Luke DA, Davidson WS, Herman S. Treatment for mental illness and substance abuse in a public psychiatric hospital. J Subst Abuse Treat 1997; 12: 129-139.
69. Bovasso GB, Alterman AI, Cacciola JS, Cook TG. Predictive validity of the Addiction Severity Index's composite scores in the assessment of 2-year outcomes in a methadone maintenance population. Psychol Addict Behav 2002; 15: 171-176.
70. Weisner C, McLellan AT, Hunkeler EM. Addiction Severity Index data from general membership and treatment samples of HMO members. J Subst Abuse Treat 2000; 19: 103-109.
71. Drake RE, Wallach MA, McGovern MP. Future directions in preventing relapse to substance abuse among clients with severe mental illness. Psychatr Serv 2005; 56: 1297-1302.